← Back to patent-cliff list
L-Adrenaline Brtartrate
Tier C — Watch / tradeL-Adrenaline Brtartrate
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Adrenoceptors
Indications (approved)：Anaemia
Regional status
US
Phase III
2025-08-11
EU
-
China
IND filed
2022-07-05
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of L-Adrenaline Brtartrate?
Approved indications include: Anaemia.
When does the L-Adrenaline Brtartrate patent expire?
No public expiry year is available for L-Adrenaline Brtartrate yet; this page updates once verified.
How do I get a quote for L-Adrenaline Brtartrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30